Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595369 · ClinicalTrials.gov registry record · Phase 2
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 963
- Enrollment target
NCT05595369: Completed Phase 2 study, sponsored by Kanecia Obie Zimmerman.
NCT05595369 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 963 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (624% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05595369, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 963 participants
- Enrollment target
Study Summary
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial with different interventions organized as appendices to the protocol. Each appendix (or sub-study) evaluates potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection, viral reactivation, and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
Primary Outcome
Appendix-specific outcome measure data will be reported under the associated NCT ID.
Interventions
- DRUG Experimental: Paxlovid 25 day dosing
- DRUG Experimental: Paxlovid 15 day dosing
- DRUG Placebo Comparator: Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 963 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 2 |
What the finished NCT05595369 record still lists
NCT05595369 is an interventional study that assigns participants to a tested intervention. The registered 963 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (624% higher).
The record links to 0 conditions, and to 3 interventions - of which Experimental: Paxlovid 25 day dosing is the first listed.
NCT05595369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05595369 about?
NCT05595369 is a clinical study titled "RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...
What is the current status of trial NCT05595369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 963 participants. The study started on 2023-07-26. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05595369?
The interventions under investigation include: Experimental: Paxlovid 25 day dosing (DRUG), Experimental: Paxlovid 15 day dosing (DRUG), Placebo Comparator: Control (DRUG).
Who is sponsoring clinical trial NCT05595369?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05595369's enrollment target sits among peer trials
963 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI